Cognitive remediation versus active computer control in bipolar disorder with psychosis: study protocol for a randomized controlled trial by Lewandowski, Kathryn Eve et al.
Cognitive remediation versus active
computer control in bipolar disorder
with psychosis: study protocol
for a randomized controlled trial
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Lewandowski, Kathryn Eve, Sarah H. Sperry, Dost Ongur, Bruce
M. Cohen, Lesley A. Norris, and Matcheri S. Keshavan. 2016.
“Cognitive remediation versus active computer control in bipolar
disorder with psychosis: study protocol for a randomized controlled
trial.” Trials 17 (1): 136. doi:10.1186/s13063-016-1275-7. http://
dx.doi.org/10.1186/s13063-016-1275-7.
Published Version doi:10.1186/s13063-016-1275-7
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318567
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
STUDY PROTOCOL Open Access
Cognitive remediation versus active
computer control in bipolar disorder with
psychosis: study protocol for a randomized
controlled trial
Kathryn Eve Lewandowski1*, Sarah H. Sperry1, Dost Ongur1, Bruce M. Cohen1, Lesley A. Norris1
and Matcheri S. Keshavan2
Abstract
Background: Cognitive dysfunction is a major feature of bipolar disorder with psychosis and is strongly associated
with functional outcomes. Computer-based cognitive remediation has shown promise in improving cognition in
patients with schizophrenia. However, despite similar neurocognitive deficits between patients with schizophrenia and
bipolar disorder, few studies have extended neuroscience-based cognitive remediation programs to this population.
Methods/Design: The Treatment to Enhance Cognition in Bipolar Disorder study is an investigator-initiated, parallel
group, randomized, blinded clinical trial of an Internet-based cognitive remediation protocol for patients with bipolar
disorder I with psychosis (n = 100). We also describe the development of our dose-matched active control paradigm.
Both conditions involve 70 sessions of computer-based activities over 24 weeks. The control intervention was
developed to mirror the treatment condition in dose and format but without the neuroplasticity-based task design and
structure. All participants undergo neuropsychological and clinical assessment at baseline, after approximately 25 hours
of study activities, post treatment, and after 6 months of no study contact to assess durability. Neuroimaging at
baseline and post treatment are offered in an “opt-in” format. The primary outcomes are scores on the MATRICS
battery; secondary and exploratory outcomes include measures of clinical symptoms, community functioning, and
neuroimaging changes. Associations between change in cognitive measures and change in community functioning
will be assessed. Baseline predictors of treatment response will be examined.
Discussion: The present study is the first we are aware of to implement an Internet-based cognitive remediation
program in patients with bipolar disorder with psychosis and to develop a comparable web-based control paradigm.
The mixed online and study-site format allows accessible treatment while providing weekly staff contact and bridging.
Based on user-provided feedback, participant blinding is feasible.
Trial registration: ClinicalTrials.gov NCT01470781; 11 July 2011.
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Background
Cognitive impairment is common in patients with bipo-
lar disorder (BD) and is associated with poorer func-
tional outcomes [1–5] and longer time to recovery after
a first episode [6]. Over time, increasing illness burden
appears to be associated with increased neurocognitive
dysfunction [7]. Despite strong associations between
cognitive impairment and functional outcomes, treat-
ment for these symptoms is inadequate. Medications
produce modest overall improvement in cognitive symp-
toms, and may even worsen some aspects of cognition
[8–11]. As few as one third of patients achieve func-
tional recovery over time [12]. At least partial disability
is reported in approximately 80 % of patients with BD;
as many as 65 % of patients report being unemployed
even after clinical recovery, and patients experience sig-
nificant disability in daily living and social functioning
[13]. As cognition is among the strongest predictors of
functional outcomes (e.g., [3, 4]), and consistent with a
European College of Neuropsychopharmacology expert
report [13], it is critical to target this key symptom di-
mension in patients with BD [1, 4, 12, 13].
Cognitive deficits in bipolar disorder
Patients with BD exhibit deficits in memory, executive
function, and processing speed/efficiency that persist
during euthymic phases and over time [14–18]; patients
with BD with a history of psychosis (BDP) may be espe-
cially cognitively impaired [14, 19, 20]. Cognitive remedi-
ation (CR) is a promising treatment approach addressing
neurocognitive dysfunction in the hopes that improved
cognitive performance will translate to better community
outcomes. A meta-analysis of 40 studies of CR for adults
with schizophrenia (SZ) found that these programs pro-
duced moderate, durable effects on cognitive functioning
[21]. A recent meta-analysis of 16 studies reported moder-
ate effects of CR on cognition in affective illness (primarily
affective psychosis) similar to findings in SZ [22]. Despite
the substantial overlap in cognitive impairments between
SZ and BD – qualitatively and in some studies quantita-
tively – only one study to date has reported outcomes
after CR in patients with BD. In a 14-session cognitive
training program focusing on neurocognitive deficits and
residual symptoms of depression in patients with BD, CR
was associated with improved executive functioning, which
was related to improved vocational performance [23].
Challenges in cognitive remediation
Typical CR paradigms require multiple training sessions
weekly, which may be prohibitive for potential study
participants. Many of the CR programs that have shown
efficacy in patients with SZ have studied chronic patients
who are able to attend sessions at community-based
programs multiple times per week, due to high levels of
disability and low instrumental role involvement (e.g.,
[24]). While patients with BD exhibit considerable dis-
ability, especially compared to premorbid functioning,
patients with SZ or schizoaffective disorder (SZA) ex-
hibit greater morbidity and disability on average [25], in-
dicating that treatments requiring multiple weekly
sessions at study sites may be unrealistic, especially for
patients who are even partially engaged in work or
school roles. With rapid advancements in online cogni-
tive training programs, there is considerable potential
for Internet-based treatments to improve access to train-
ing for patients. However, reports suggest that face-to-
face “bridging” sessions, which create an opportunity for
subjects to explicitly consider implementation of newly-
developed cognitive skills in daily life, are important for
generalizing the effect of CR treatments to daily func-
tioning [26]. Thus, a tension exists between reducing
participant burden through remote access and conduct-
ing treatment delivery in the most effective manner.
Inclusion of adequate comparison conditions is chal-
lenging in CR paradigms given the active nature of the
treatment. “Placebo” conditions are particularly challen-
ging with these types of programs, as participants are
keenly aware of the elements of participation throughout
the program. The majority of projects that have included
an active control group have selected individual or group
rehabilitative or therapeutic activities such as Enriched
Supportive Therapy [27], supportive group therapy [28],
cognitive behavioral therapy (CBT) [29], Integrated Psy-
chological Therapy [30], treatment as usual plus group
activities [31], vocational rehabilitation, occupational
therapy, supported employment [32–34], computer skills
training plus day treatment [35] or social skills training
[36]. These types of comparison conditions allow for the
control of hours of study staff contact and other factors
associated with involvement/adherence to a psychosocial
intervention; however, they do not control for other as-
pects of the CR intervention such as computer interaction
or game engagement, and they do not reasonably permit
double-blindness – a particular challenge for interpretation
of results as poor masking of treatment allocation in
clinical trials has been shown to inflate treatment effects [21].
Recently several game-format comparison conditions
have been developed for CR paradigms attempting to
match the computer/gaming elements of CR but with
nonspecific content; these include computer games or
action videogames [24, 37–39], some paired with add-
itional group or coaching activities to match for other
elements of the active treatment condition [37, 38]. No
studies to date have published findings including Internet-
based controls that can be overseen via remote access;
however, as Internet-based CR programs are in active
development and use, comparable Internet-based para-
digms that will permit active comparison are needed.
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CR programs vary considerably in terms of method-
ology, and it is not clear which if any aspect(s) of treat-
ment design influence outcomes. Variables to consider
include total duration of treatment, number of sessions,
treatment intensity (i.e., “density” of sessions), drill and
practice approaches versus strategy use, and individual
versus group format, among many other characteristics.
A meta-analysis of 40 CR studies did not find any effect
of treatment characteristics on cognitive outcomes [21],
although programs that included strategy use showed a
trend toward greater functional improvements [21, 40].
Finally, it is possible that participant characteristics may
influence treatment response. In their meta-analysis,
Wykes and colleagues [21] found no effect of most base-
line characteristics including age, baseline cognitive func-
tioning, or chlorpromazine equivalents on outcomes after
CR; however, lower clinical symptoms at baseline were as-
sociated with greater effects of treatment on cognitive
outcomes.
In this report we aimed to (1) describe our Internet-
based neuroplasticity-informed CR protocol for BDP, (2)
describe the development of our Internet-based, dose-
matched active control, and (3) assess the ability of our
study design to remain blinded.
Methods/Design
This study and all associated procedures comply with
the ethical standards of the relevant national and institu-
tional committees on human experimentation and with
the Helsinki Declaration of 1975, as revised in 2008, and
have been approved by the McLean Hospital Institutional
Review Board. This project is registered with Clinical-
Trials.gov (NC01470781), and all procedures and report-
ing of our primary and secondary outcomes will follow
Consolidated Standards of Reporting Trials (CONSORT)
2010 guidelines [41].
Participants
Outpatients with idiopathic BD Type I with a history of
psychosis between the ages of 18 and 50 (n = 100) are
recruited through the McLean Hospital Psychotic Disor-
ders Program and fliers posted at the hospital (See
Fig. 1). All participants are informed of the study proce-
dures, including randomization to either treatment or
control conditions, and provide written informed con-
sent. All patients are symptomatically stable outpatients
at the time of enrollment, and have been out of the
hospital for at least 1 month with Positive and Negative
Syndrome Scale (PANSS) scores under 75, ratings of 3
(mild) or less on the PANSS psychosis items, and Young
Mania Rating Scale (YMRS) scores below 6. We set these
criteria based on findings that baseline clinical symptoms
are associated with treatment response [21]. To reduce
medication confounds, only patients on monotherapy
lithium or valproate plus an atypical antipsychotic (ex-
cluding clozapine) are eligible. Patients taking anticholin-
ergic medications are excluded, as they produce cognitive
dysfunction and may interfere with CR response [42, 43].
Exclusion criteria include: substance abuse in the past
month; substance dependence in the past year; history of
seizure disorder or head injury with loss of consciousness;
anticholinergic medications (e.g., benztropine), clozapine,
and topiramate.
Power calculation
For the total sample, we aim to recruit 100 partici-
pants, which will yield approximately 50 participants
per group. This sample size is based on power calcu-
lations using a conservative estimate of effect size of
two thirds of the effects on cognition of published
findings using similar duration and paradigm CR in
patients with SZ (d = 0.74–0.89) [24, 44] and anticipating
attrition at approximately 15 % [44]. One-tailed alpha for
sample-size estimates was selected because directional ef-
fects are hypothesized (CR greater than control interven-
tion) and have been established in other populations.
Thus, with alpha at 0.05 we have 80 % power to detect ef-
fects of 0.54 or greater.
Assessment measures
Cognition
Cognitive functioning was assessed using the battery
developed by the Measurement and Treatment Research
to Improve Cognition in Schizophrenia (MATRICS)
initiative [45]. While the MATRICS Consensus Cogni-
tive Battery (MCCB) was developed for cognitive assess-
ment in SZ, the MCCB has been validated in patients
with BD [46, 47]. The MATRICS battery includes 10
tasks that measure processing speed (Brief Assessment
of Cognition in Schizophrenia Symbol Coding, Animal
Fluency, Trails A), attention (Continuous Performance
Test), working memory (WMS-III Spatial Span, Letter-
Number Span), verbal learning (Hopkins Verbal Learning
Test – Revised), visual learning (Brief Visuospatial Memory
Test – Revised), problem solving (Neuropsychological
Assessment Battery Mazes) and social cognition (Mayer-
Salovey-Caruso Emotional Intelligence Test). Total ad-
ministration time is 60–90 minutes.
Clinical and community functioning
Clinical and community functioning assessment included:
the Positive and Negative Syndrome Scale (PANSS; [48]);
Young Mania Rating Scale (YMRS; [49]); Montgomery-
Asberg Depression Rating Scale (MADRS; [50]); Multno-
mah Community Ability Scale (MCAS; [51]); Social and
Occupational Functioning Assessment Scale (SOFAS;
[52]). The MCAS measures functioning in psychiatric
patients in multiple domains (e.g., social effectiveness,
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independence, meaningful activities). The SOFAS is a
100-point scale similar to the Global Assessment of Func-
tioning that evaluates social and occupational functioning
not directly influenced by symptom severity.
Feedback survey
A user feedback survey was created by our group to
evaluate participants’ experiences using the CR or con-
trol activities, and to evaluate participants’ beliefs about
their study assignment to test the effectiveness of the
blind. The first 13 items ask about tolerability, including
enjoyment of the tasks, especially compared to other
types of treatment, perception of difficulty, stressfulness
of the activities, feelings of competency generated by
participation, and whether users would continue to par-
ticipate if given the option. Responses are given using a
Likert scale (1–5) with higher scores indicating stronger
response; 4 of the 13 items inquired about negative
experiences such that higher scores were associated with
more negative responses; these items were reverse scored
so that in all cases a higher score indicates more posi-
tive response. Cumulative scores range from 13 to 65.
Subjects were also asked in a forced-choice item to
indicate which treatment condition they believed they
were assigned to, and then asked to rate the certainty
of their selection.
Additional outcome measures
We are also collecting neuroimaging data and measures of
reward processing at baseline and post treatment in order
to begin to examine baseline predictors of treatment re-
sponse and mechanisms of action of the treatment. These
procedures are offered in an “opt-in” format, meaning that
participants do not have to consent to (or be eligible for)
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram: Treatment to Enhance Cognition in Bipolar Disorder Allocation
and study flow
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neuroimaging or reward processing tasks in order to par-
ticipate in the CR trial.
CR treatment
Given that this was the first extension of computer-
based, drill and practice CR to patients with BDP, and
the considerable overlap in terms of cognitive dysfunc-
tion in SZ and BDP, we selected a CR paradigm that has
demonstrated efficacy in patients with SZ [24]. We se-
lected a dose that – based on previous findings – was
likely to be adequate to demonstrate cognitive effects, so
that failure of the treatment would not likely be due to
under-dosing. Active treatment involved 70 hours of
computer-based activities at an intensity of three ses-
sions per week using the BrainWorks programs by
PositScience. Games were developed based on a recov-
ery model of neural plasticity [53]. Many cognitive defi-
cits (e.g., memory) are believed to be secondary to more
core processing issues, including slow processing speed
and poor encoding of sensory stimuli. Thus, these pro-
grams target root causes of abnormalities in brain func-
tion using a “bottom-up” approach, training sensory
processing early in the program and adding “higher-
order” tasks as the activities progress. Programs are de-
signed to improve processing speed and efficiency (e.g.,
quick and accurate stimulus identification), reaction
time, attention, concentration, and working memory.
Programs self-adjust based on user performance to keep
participants working at 80 % proficiency.
The CR paradigm is accessed online through a web
portal created by BrainWorks, which allows study partic-
ipants to engage with the program from any computer
with Internet access. In order to reduce travel burden
and allow greater flexibility for participants to complete
the sessions they are allowed to complete two of the
three weekly sessions remotely; one weekly session is to
be completed with the study staff at the study site in
order to provide coaching and bridging opportunities.
Study administrators track participant adherence re-
motely through an administrator account, which allows
staff to check when participants logged onto their pro-
grams and what they did while they were there.
Computer control
We developed a computer-based control that mirrored
the CR program in number of training sessions, online
format, administrator contact, and general activity for-
mat so as to control for as many nonspecific effects of
the CR treatment as possible. However, the control does
not include tasks that should substantially address the
cognitive deficits typical of BDP. Thus, the control condi-
tion involves engagement in active computer games, but
without the step-wise, “bottom-up” approach or adaptive
nature of the tasks. In order to monitor adherence to the
protocol – a particular concern given the remote access to
games offered in the CR condition – it was necessary to
develop a comparison condition that also permitted study
staff to track remote usage during at-home sessions. Ses-
sions were created using generic games administered via
the online interface Sporcle (www.Sporcle.com), a collec-
tion of thousands of quiz-type activities. We carefully se-
lected several hundred games to include a broad array of
activities that most people have knowledge of. Games in-
cluded identification activities (e.g., identify pictured fruits
and vegetables), content-based activities (e.g., label states
on a map), and some timed activities (e.g., complete as
many basic arithmetic problems as possible in 5 minutes).
Data from thousands of users documenting accuracy rates
for each quiz are freely available online; we used these
data to rate each quiz for difficulty based on total quiz
completion/accuracy rates. This was undertaken to ensure
that games were not overly difficult. Games were excluded
if they had an accuracy rate of less than 40 %. Average ac-
curacy for selected quizzes was approximately 73 %.
Similar to the CR condition, an administrator account
allows study staff to track subject activity via a social
networking-style format that allows the administrator to
request that participants allow themselves to be followed
online. Through this process the study administrators
are able to determine when participants logged in, which
games they engaged in, and what their response accur-
acy was. In order to maintain confidentiality all subjects
are assigned a study-based user identity (ID) that allows
the administrator to identify individual participants
without revealing any personal information.
Games were divided into 70 sessions of prescribed ac-
tivities to mirror the format and length of the treatment
condition. Types of activities were distributed so that no
single session included only one type of game (e.g., all
rapid-response games). Participants are given “prescrip-
tion cards” each week listing the games they are to en-
gage in during each weekly session. As in the CR
condition, participants may elect to play two of the three
weekly sessions remotely via web access; one weekly ses-
sion is completed at the study site with staff.
Procedures
Randomization was started using a simple randomization
approach, but due to increasing imbalance this approach
was switched to a blocked random design with a block size
of 10. The Research Randomizer tool (www.Randomizer.
org) was used to generate the random allocation sequence.
The principal investigator (PI), KEL, generated the se-
quence, which was given to enrollment staff who are re-
sponsible for group assignment. We employed a parallel
design with an allocation ratio of 1:1. The randomization
key is kept by a single staff member, who provides the
treatment and/or communicates assignment information
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directly to treatment staff. Assessment staff are not in-
formed of group assignment (see below). Participants are
not informed of their group assignment. During the con-
sent process participants are explicitly informed that par-
ticipation in the study involves random assignment to
either the treatment condition or an active control, that
they may be assigned to the control condition, and that
they will not be informed of their group assignment. Par-
ticipants are informed that they may request knowledge of
their study assignment at the end of the follow-up period.
In this study, both patients and assessment staff re-
main blind to group membership through completion of
the follow-up assessment; however, treatment adminis-
trators are not able to remain blind to group assignment.
Treatment administrators meet with participants weekly
to discuss their progress and one session weekly is com-
pleted on site with treatment staff; thus, treatment ad-
ministrators are not able to remain blinded to group.
We attempt to maintain the participant and assessment
staff blind in several ways: enrollment staff and treat-
ment administrators never conduct assessments at any
time point; the assessment staff are not located in the
same office space as the treatment administrators, and
do not observe or participate in weekly sessions; partici-
pants are reminded that assessment staff cannot know
which group they were assigned to and it is requested
that any mention of the activities be avoided during as-
sessments; subject IDs and enrollment dates are not in-
cluded in the database accessible to staff who are blind to
group membership, and non-sequential dummy codes are
created for the purposes of data access by blinded staff
members. The feedback survey described above contains
two questions regarding participants’ beliefs about group
membership, which aim to assess which group partici-
pants believe they were in, and their certainty about this
belief. These data are used to help us determine whether
or not we were able to maintain the blind.
Both conditions involve 70 sessions (3 per week for
24 weeks). All participants attend one session per week at
the study site; two sessions are completed remotely via
Internet login. Weekly in-person sessions include an up-
date (CR and control) and a bridging session (CR only),
plus one CR or control session with study staff. Study staff
are able to track user progress and adherence via an ad-
ministrator account, and send reminder calls or emails
upon request or if participants do not complete their at-
home sessions in a timely fashion.
Assessments are conducted at baseline, midpoint (after
approximately 25 hours of training) post treatment (within
1 week of completing the treatment/control), and at
follow-up (6 months after completion of the treatment/
control). All subjects complete clinical and cognitive
assessments; neuroimaging is presented as an “opt in”
portion of the study. Clinical and cognitive assessments
are typically conducted in the same session. Baseline
assessments occur 2 weeks or less prior to the start
of training; post-treatment assessments are con-
ducted within 1 week of completing the final train-
ing session.
Statistical approach
Our primary aim is to evaluate the effect of CR on cog-
nition in patients with BDP compared to a computer-
based control. The primary outcome measures of
interest are MCCB scores. Primary analyses will be
based on composite scores; secondary analyses will
examine domain scores if composite findings are signifi-
cant. The main analysis will be an intent-to-treat analysis,
which includes all randomized subjects regardless of com-
pliance to reduce potential for post-randomization bias
and inflation of Type I errors. We will use a linear mixed
effects model; inclusion of random effects accounts for
the correlation among repeated measures. Outcome
measures will include the three post-baseline measures of
cognition; the baseline measure will be adjusted for by
including it as a covariate. The test of no treatment differ-
ence will be based on a joint test of the group and group-
by-time interaction.
The secondary aim is the examination of potential
mechanisms for changes in community functioning. It is
hypothesized that cognitive (but not clinical) change will
mediate changes in community functioning. Thus, com-
munity functioning will be modeled adjusting for com-
posite neuropsychological (or clinical) change using
linear mixed effects models to relate changes in commu-
nity functioning to treatment group while adjusting for
differences in cognitive (or clinical) change.
Discussion
The present study is the first we are aware of to imple-
ment an Internet-based CR paradigm in patients with
BDP and to develop a comparable Internet-based control.
The hybrid online/study site format allows accessible
treatment while providing opportunities for staff contact
and bridging. Our newly developed web-based control is
comparable to the treatment in terms of administration
and interface: it is dose-matched, including requirements
for in-person visits and study staff contact; administrator
oversight permits adherence monitoring; sessions are
similar in format to those of the CR paradigm.
Based on preliminary feedback from our feedback sur-
vey, participant blindness can be successfully maintained
with our present paradigm. Responses from the first 22
participants to complete the survey showed that subjects
did not differ in terms of which condition they believed
they were randomized to: 86 % of subjects in the treat-
ment and 63 % of subjects in the control reported be-
lieving that they had participated in the active CR
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treatment (Chi2 = 1.56, p = 0.20). On a three-point scale
evaluating confidence in their belief of their reported
assignment (very (3), somewhat (2), or not at all (1)),
participants had low confidence in their ratings in both
treatment and control conditions (mean = 1.64, SD = 0.63
and mean = 1.63, SD = 0.92, respectively; t = 0.05, p =
0.96). Our newly developed active control permits exam-
ination of specific elements of our CR paradigm by
accounting for many of the nonspecific elements of
participation in the study while maintaining the partici-
pant and assessment staff blind.
Ultimately, our primary aim is to evaluate efficacy of
this CR program compared to active control. We also
aim to examine predictors of treatment adherence and
response, and neurobiological mechanisms of action
using magnetic resonance imaging (MRI) techniques.
Better understanding of both predictors of treatment re-
sponse and the mechanisms of action of CR will allow
further refinement and individualization of treatment
efforts. We will also be able to examine the role of base-
line characteristics, reward processing, and neurobio-
logical response in the relationship between cognitive and
functional outcomes.
Limitations
While extensive efforts will be made to minimize missing
data, attrition is a major concern in long-duration CR par-
adigms. We have implemented several techniques for min-
imizing attrition including monetary bonuses for reaching
session milestones (awarded after 10 sessions, 30 sessions,
and 50 sessions, in increasing amounts), regular phone
and email contact from study staff reminding subjects to
complete sessions at home, weekly in-person visits, and
weekly session tracking feedback that displays progress
and time to next bonus graphically. However, attrition re-
mains a concern. Thus, for all analyses we will use statis-
tical methods that incorporate partially observed data, and
assess the sensitivity of results to different assumptions
about the mechanism by which data are missing.
In any clinical trial the potential for bias in recruit-
ment or allocation is a concern. All potential subjects
meeting enrollment criteria are offered the opportunity
to participate; special efforts will be made to ensure that
the enrollment of women and minorities matches the
demographics of the region. Allocation is done using a
blocked random design based on number sequence,
without consideration of participant characteristics.
Thus, the main source of bias in this study is likely in
non-random characteristics of participants who do or do
not adhere to the study procedures. As noted above, we
will use statistical methods to minimize the potential for
such post-randomization bias.
In terms of masking, we have developed an approach
that maximizes our ability to include blinding of
participants and study staff; however, as noted above,
while assessment staff are able to remain blinded to
study assignment, due to the nature of the intervention
treatment staff are not. Thus, there is the potential for
information about group membership to inadvertently
become known to participants or to assessment staff.
Because poor masking of treatment allocation is associ-
ated with potential inflation of treatment effects [21],
the issue of blinding in treatment studies is of key im-
portance. Our post-treatment feedback survey suggests
that we have been able to maintain participant blinding,
but the potential for a break in the blind remains a
limitation.
Patients with BD comprise a highly heterogeneous
group, creating the potential for dilution of findings of
efficacy within subsamples that are more homogeneous.
We attempted to increase homogeneity of our sample by
restricting enrollment to patients with a history of
psychosis, which has been shown to be associated with
cognition, and by imposing age and medication restric-
tions; however, this may restrict generalizability of our
findings to patients with specific illness characteristics. If
our findings continue to support the feasibility, tolerabil-
ity, and ultimately efficacy of CR in patients with BDP,
future work may extend this treatment to patients with
different baseline characteristics in order to examine the
question of generalizability and design protocols targeted
to subgroups of patients with BDP.
Trial status
Patient enrollment began in July 2011. By July 2015 76
participants had been enrolled.
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